StockNow
Log in
U.S. Markets

Biogen (BIIB) Q2 2026 (USD): adj. EPS 3.60 (exp. 3.02), Revenue 2.7bln (exp. 2.46bln); sees FY adj. EPS at 12.00-13.00 (exp. 11.82), sees Q2 adj. EPS 3.60 (exp. 3.04)

StockNow breaking-news AI analysis

Biogen beat Q2 estimates with $2.74B revenue and $3.60 EPS. FY2026 guidance was lowered to $12–$13 to reflect the $5.6B Apellis acquisition costs, despite growth in Leqembi sales.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYU.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)

Geopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement